Table 4 Overall results for men with no prior genetic testing/screening.
From: Diagnosing hereditary cancer predisposition in men with prostate cancer
ProstateNext | Other MGPT | |||||
|---|---|---|---|---|---|---|
N | 277 | 1385 | ||||
Overall test result (%) | ||||||
Positive | 26 | 9.4% | 168 | 12.1% | ||
Inconclusive | 44 | 15.9% | 324 | 23.4% | ||
Moderate risk PV | 2 | 0.7% | 13 | 0.9% | ||
MUTYH carrier | 0 | 0.0% | 17 | 1.2% | ||
Negative | 205 | 74.0% | 863 | 62.3% | ||
Gene | PV/VLP | Total # tested | % | PV/VLP | Total # tested | % |
BRCA2 | 9 | 277 | 3.2% | 47 | 1224 | 3.8% |
BRCA1 | 1 | 277 | 0.4% | 9 | 1223 | 0.7% |
TP53 | 1 | 277 | 0.4% | 4 | 1367 | 0.3% |
MLH1 | 0 | 277 | 0.0% | 2 | 1224 | 0.2% |
MSH2 | 0 | 277 | 0.0% | 11 | 1224 | 0.9% |
MSH6 | 0 | 277 | 0.0% | 5 | 1224 | 0.4% |
PMS2 | 0 | 277 | 0.0% | 7 | 1224 | 0.6% |
EPCAM | 0 | 277 | 0.0% | 1 | 1222 | 0.1% |
CHEK2 | 3 | 277 | 1.1% | 35 | 1199 | 2.9% |
PALB2 | 1 | 277 | 0.4% | 6 | 1169 | 0.5% |
ATM | 5 | 277 | 1.8% | 32 | 1145 | 2.8% |
NBN | 2 | 277 | 0.7% | 2 | 1057 | 0.2% |
RAD51D | 0 | 277 | 0.0% | 0 | 1031 | 0.0% |
MUTYH | 0 | 0 | - | 23 | 1151 | 2.0% |
BRIP1 | 0 | 0 | - | 1 | 1037 | 0.1% |
RAD51C | 0 | 0 | - | 1 | 1038 | 0.1% |
MRE11A | 0 | 0 | - | 2 | 1031 | 0.2% |
BARD1 | 0 | 0 | - | 3 | 1030 | 0.3% |
APC | 0 | 0 | - | 8 | 1004 | 0.8% |
CDKN2A | 0 | 0 | - | 5 | 867 | 0.6% |
HOXB13 | 6 | 277 | 2.2% | 2 | 339 | 0.6% |
SDHD | 0 | 0 | - | 1 | 293 | 0.3% |
MITF | 0 | 0 | - | 3 | 291 | 1.0% |
FH | 0 | 0 | - | 1 | 288 | 0.3% |
FLCN | 0 | 0 | - | 1 | 283 | 0.4% |
MAX | 0 | 0 | - | 1 | 251 | 0.4% |
BAP1 | 0 | 0 | - | 1 | 244 | 0.4% |
FANCC | 0 | 0 | - | 1 | 84 | 1.2% |
